本帖最后由 老马 于 2013-3-13 13:43 编辑
3 B/ u0 s8 Y; D; c; w m+ V1 |
$ s5 X3 C1 [7 m健择（吉西他滨）+顺铂+阿瓦斯汀 E4 K# U; `, s2 }2 F; f
Gemzar +Cisplatin + Avastin
' J0 f# \7 u& X9 ?+ v" s* mhttp://annonc.oxfordjournals.org/content/21/9/1804.full! f; p/ a4 |/ y/ q, Z* Q3 S0 B
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) : ^. ~; A% N: |% z
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 9 G2 V( X* X* b8 B# g. A$ \& Z
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ! L- e4 j2 O6 o- [, A
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 284)
$ O: B# q! L, U! p2 n" K
华为网盘附件：$ A' A! N6 x' X& t( [ }: x
【华为网盘】ava.JPG
0 _# ^9 Q8 v% O% c( o' A% ~ |
显身卡
